Serum Transferrine value as a Tumor marker

We analyzed the serum levels of transferrin (TRF) in 60 patients with cancer having metastasis and without metastatis. We observed the mean value of the serum TRF as 2,22±0,62 g/L in cancer patients and 1,81±030 g/L in metastatic patients and 2,63±0,58 gr/L in non-metastatic patients. The mean value of the serum TRF was 3,00±0,57 gr/L in control group. We found a significant difference between the control group and patients have non-metastasis and also between control group and patients have metastasis (p: 0,0001 and p: 0,0000, respectively). But there was not a significant difference between control group and nonmetastatic group (p: 0,2466). According to our results, we can suggest that in terms of the determining metastasis in patients with cancer, the serum levels of the TRF is readily appliable and useful test.

SERUM TRANSFERRİN'İN TÜMÖR MARKER'I OLARAK DEĞERLENDİRİLMESİ

60 metastatik ve nonmetastatik kanserli hastada serum transferrin (TRF) düzeyleri tayin edildi. Serum TRF düzeylerini kanserli hasta grubunda 2,22±0,61 g/L, metastatik kanserli grupta 1,81±0,30 g/L, nonmetastatik kanserli grupta 2,63±0,58 g/L bulduk. Kontrol grubunda ise serum TRF düzeyi 3,00±0,57 g/L idi. Kontrol grubu ve kanserli hasta grubu arasýnda anlamlý fark bulundu (p: 0,0001 ). Ayrýca nonmetastik ve metastatik kanserli hasta grubu arasýnda (p: 0,0000) ve kontrol grubu ile metastatik kanserli grup arasýnda anlamlý fark vardý (p: 0,0000). Ama kontrol grubu ve nonmetastatik kanserli hasta grubu arasýnda anlamlý fark yoktu (p: 0,2466). Bu sonuçlara göre malign hastalýklarda metastaz varlýğýnýn gösterilmesinde serum TRF tayininin kolaylýkla uygulanabilir ve yararlý bir test olduğu görüldü.